Trial Information Summary - NIVORAD

NIVORAD - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer (NSCLC), progressing after first or second line chemotherapy.



The information contained in this document is intended for discussion with your health professional to help determine your potential eligibility.

The aim of this study is to determine the activity and safety of treating an asymptomatic, extrathoracic metastasis with a single fraction of stereotactic ablative body radiation (SABR), during immunotherapy with nivolumab in advanced non-small cell lung cancer (NSCLC) progressing after 1 or 2 lines of chemotherapy. Nivolumab is an antibody, directed against the programmed cell death-1 receptor (PD-L1), with significant activity in advanced NSCLC. The rationale for this trial is that stereotactic ablative body radiation therapy (SABR) will release tumour-related antigens that will increase the systemic activity of immunotherapy with nivolumab.

Inclusions

- Histologically or cytologically confirmed diagnosis of NSCLC;
- At least one site of metastasis which is suitable for stereotactic radiotherapy, but for which radiotherapy is not urgently required at the time of enrolment;
- At least one that is separate and in addition to the lesion nominated for irradiation. This lesion cannot have been irradiated previously;
- Must have relapsed after receiving 1 or 2 lines of chemotherapy for advanced disease including a platinum-based doublet;
- ECOG performance status of 0 or 1 at the time of randomisation;
- Adequate bone marrow function. Blood transfusions are permissible;
- Adequate liver function: Alanine transaminase less than or equal to 3 x upper limit of normal (ULN), Aspartate aminotransferase less than or equal to 3 x ULN, Total bilirubin less than or equal to 1.5 x ULN;
- Adequate renal function: Serum creatinine less than or equal to 1.5 x ULN or Creatinine clearance greater than or equal to 40 mL/min;
- Tumour tissue must be available for PD-L1 testing;
- Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments.

Exclusions

- Active or suspected autoimmune disease, except vitiligo, type 1 diabetes mellitus, residual hypothyroidism requiring only hormone replacement, psoriasis not requiring systemic treatment;
- Any condition requiring systemic treatment with either corticosteroids (greater than 10mg daily corticosteroid) or other immunosuppressive medications within 14 days of study drug administration;
- Patients with leptomeningeal or uncontrolled brain metastases. Actionable mutation for which an approved, targeted therapeutic is available;
- Chemotherapy in the last 4 weeks, Radiotherapy in the last 6 weeks. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways. Current treatment with other investigational drugs or anti-cancer therapy;
- Life expectancy of less than 3 months;
- History of another malignancy within 3 years prior to randomisation. Past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible;
- Positive test for hepatitis B virus surface antigen or antibodies to hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection. History of other significant infection, including HIV. Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol;
- Pregnancy, lactation, or inadequate contraception.

This is a summary document of the inclusion and exclusion criteria of the study.
Please contact your oncologist or GP to discuss the full details of this trial.

CTC Trial Coordinator
NIVORAD@ctc.usyd.edu.au

ALTG Program Manager
altg@lungfoundation.com.au

Participating sites

State	Site
NSW	Chris O'Brien Lifehouse
	Prince of Wales Hospital
	Royal North Shore Hospital
	Sydney Adventist Hospital
	The Tweed Hospital
QLD	Genesis Cancer Care
	Nambour General Hospital
	Princess Alexandra Hospital
	Royal Brisbane and Women's Hospital
	Townsville Hospital
SA	Flinders Medical Centre
	Royal Adelaide Hospital
TAS	Royal Hobart Hospital
VIC	Austin Hospital
	Peninsula South Eastern Haematology & Oncology Group
	St Vincent's Hospital
	Western Health Sunshine Lung Oncology
WA	Sir Charles Gairdner Hospital
NZ	Auckland City Hospital - Auckland District Health Board